Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Market News
UBS joins index funds, Goldman's, & Morgans in Pro Medicus fan club
Share Gainers
ALL ORDINARIES finishes higher Tuesday: 8 shares you missed
52-Week Highs
Why the Austal share price is sailing a new 8-year high today
52-Week Highs
The Clinuvel Pharmaceuticals share price is up 236% in 12 months
Share Market News
Quarterly rebalance: Afterpay added to ASX 100, Syrah Resources kicked out of ASX 200
Share Fallers
Why Beach, Clinuvel, Kogan, & Zip Co shares dropped lower today
Share Fallers
Why the Clinuvel Pharmaceuticals share price crashed 11% lower today
52-Week Highs
Is it too late to buy Telstra and these high-flying ASX shares?
Share Market News
Insiders have been buying Macquarie and these ASX shares
Share Gainers
Why Nearmap and these ASX shares have doubled in value in 12 months
Share Gainers
Clinuvel Pharmaceuticals shares higher on strong quarterly sales growth
Share Fallers
Why API, Clinuvel, Galaxy Resources, & Zip Co dropped lower today
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
